At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NMTR 9 Meters Biopharma Inc.
Delisted 12-23 08:42:23 EST
0.0722
+0.0000
0.00%
High0.0722Low0.0722Vol0.00
Open0.0722D1 Closing0.0722Amplitude0.00%
Mkt Cap1.04MTradable Cap920.60KTotal Shares14.46M
T/O0.00T/O Rate0.00%Tradable Shares12.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Dow Jumps Over 300 Points; Morgan Stanley Posts Upbeat Earnings
Benzinga  ·  2023-07-19
Dow Jumps Over 300 Points; Morgan Stanley Posts Upbeat Earnings
BRIEF-9 Meters Biopharma Inc And Units Files For Bankruptcy Protection
Reuters  ·  2023-07-18
BRIEF-9 Meters Biopharma Inc And Units Files For Bankruptcy Protection
BUZZ-9 Meters Biopharma slumps after filing for bankruptcy protection
Reuters  ·  2023-07-18
BUZZ-9 Meters Biopharma slumps after filing for bankruptcy protection
UPDATE 1-Drug developer 9 Meters Biopharma files for bankruptcy protection
Reuters  ·  2023-07-18
UPDATE 1-Drug developer 9 Meters Biopharma files for bankruptcy protection
BRIEF-9 Meters Biopharma Gets Notice Of Delisting Or Failure From Nasdaq
Reuters  ·  2023-06-17
BRIEF-9 Meters Biopharma Gets Notice Of Delisting Or Failure From Nasdaq
9 Meters Biopharma slips 16% as CEO departs
seekingalpha  ·  2023-05-30
9 Meters Biopharma slips 16% as CEO departs
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
ACCESSWIRE  ·  2023-05-30
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
9 Meters Biopharma Inc - Co Submitted Plan Of Compliance To Nasdaq To Regain Compliance With Stockholders' Equity Requirement
T-Reuters  ·  2023-05-22
9 Meters Biopharma Inc - Co Submitted Plan Of Compliance To Nasdaq To Regain Compliance With Stockholders' Equity Requirement
Maxim Group Keeps Their Hold Rating on 9 Meters Biopharma (NMTR)
TIPRANKS  ·  2023-05-18
Maxim Group Keeps Their Hold Rating on 9 Meters Biopharma (NMTR)
9 Meters Biopharma Q1 EPS $(1.02) Misses $(0.78) Estimate
Benzinga  ·  2023-05-16
9 Meters Biopharma Q1 EPS $(1.02) Misses $(0.78) Estimate
9 Meters Biopharma GAAP EPS of -$1.02 misses by $0.24
seekingalpha  ·  2023-05-16
9 Meters Biopharma GAAP EPS of -$1.02 misses by $0.24
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
ACCESSWIRE  ·  2023-05-16
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
BRIEF-9 Meters Biopharma Enters Into Forbearance Agreement With Institutional Investor
Reuters  ·  2023-04-27
BRIEF-9 Meters Biopharma Enters Into Forbearance Agreement With Institutional Investor
9 Meters eyes FDA filing in H2 to start trial of obesity drug NM-136
seekingalpha  ·  2023-04-05
9 Meters eyes FDA filing in H2 to start trial of obesity drug NM-136
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
ACCESSWIRE  ·  2023-04-05
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
Analysts Offer Insights on Healthcare Companies: Theriva Biologics (TOVX) and 9 Meters Biopharma (NMTR)
TIPRANKS  ·  2023-04-01
Analysts Offer Insights on Healthcare Companies: Theriva Biologics (TOVX) and 9 Meters Biopharma (NMTR)
9 Meters Biopharma Inc As Of Dec 31 Had Total Cash And Cash Equivalents Of About $29.7 Million
T-Reuters  ·  2023-03-28
9 Meters Biopharma Inc As Of Dec 31 Had Total Cash And Cash Equivalents Of About $29.7 Million
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
ACCESSWIRE  ·  2023-03-28
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
9 Meters Biopharma Cut to Hold From Buy by Truist Securities
Dow Jones  ·  2023-03-20
9 Meters Biopharma Cut to Hold From Buy by Truist Securities
9 Meters downgraded to hold from buy at Truist
Dow Jones  ·  2023-03-20
9 Meters downgraded to hold from buy at Truist
No data available

Introduction

Company Name.
9 Meters Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Issue price:
--